COVID-19 and COMORBIDITIES

Year 2020, Volume: 3 Issue: Özel Sayı, 36 - 43, 05.08.2020

Abdüsselam Şekerci

Abstract

A novel coronavirus was identified in Wuhan in December 2019 and it rapidly spread throughout China, followed by in other countries. The aim of this study is to investigate the effects of comorbidities on patients with COVID-19 and to give information about their management. The electronic databases PubMed and Google Scholar have been used to assess comorbidities and clinical characteristics of COVID-19. Severe disease predominantly occurs in adults with underlying medical comorbidities or advanced age. Comorbidities and other conditions that associated with morbidity and mortality include hypertension, diabetes mellitus, cardiovascular disease, chronic lung disease, cancer (particularly metastatic disease, lung cancer, and hematologic malignancies) and chronic kidney disease. As the number of comorbidity increases, patients' clinic progresses more severely. A comprehensive assessment and good management of comorbidities can help patients with COVID-19 achieve a better outcome.

Keywords

COVID-19, comorbidities, diabetes, chronic kidney disease, cancer

References

• 1. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).
• 2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention [published online ahead of print, 2020 Feb 24]. JAMA. 2020;10.1001/jama.2020.2648. doi:10.1001/jama.2020.2648
• 3. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. Published 2020 May 22. doi:10.1136/bmj.m1966
• 4. McIntosh K. Coronavirus disease 2019 (COVID-19): Clinical features. In: Up To Date [online]. Available at: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-clinical-features?source=bookmarks_widget. (Accessed June 23, 2020)
• 5. Knapp S. Diabetes and infection: is there a link? - A mini-review. Gerontology. 2013;59(2):99–104. doi: 10.1159/000345107.
• 6. Petrie John R., Guzik Tomasz J., Touyz Rhian M. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Canadian J Cardiol. 2018;34(5):575–584. doi: 10.1016/j.cjca.2017.12.005.
• 7. Geerlings S.E., Hoepelman A.I. Immune dysfunction in patients with diabetes mellitus (DM) FEMS Immunol Med Microbiol. 1999;26(3–4):259–265. doi: 10.1111/j.1574-695X.1999.tb01397.x. Epub 1999/11/27 PubMed PMID: 10575137.
• 8. Moutschen M.P., Scheen A.J., Lefebvre P.J. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab. 1992;18(3):187–201. Epub 1992/05/01. PubMed PMID: 1397473.
• 9. Ilyas R., Wallis R., Soilleux E.J., Townsend P., Zehnder D., Tan B.K. High glucose disrupts oligosaccharide recognition function via competitive inhibition: a potential mechanism for immune dysregulation in diabetes mellitus. Immunobiology. 2011;216(1–2):126–131. doi: 10.1016/j.imbio.2010.06.002. Epub 2010/08/03. PubMed PMID: 20674073; PubMed Central PMCID: PMCPMC3088832.
• 10. Lange P., Groth S., Kastrup J., Mortensen J., Appleyard M., Nyboe J. Diabetes mellitus, plasma glucose and lung function in a cross-sectional population study. Eur Respir J. 1989;2(1):14–19. Epub 1989/01/01 PubMed PMID: 2651148.
• 11. Yang J.K., Feng Y., Yuan M.Y., Yuan S.Y., Fu H.J., Wu B.Y. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623–628. doi: 10.1111/j.1464-5491.2006.01861.x. Epub 2006/06/09. PubMed PMID: 16759303.
• 12. Banik GR, Alqahtani AS, Booy R, Rashid H. Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. Virol Sin. 2016;31(1):81-84. doi:10.1007/s12250-015-3679-z
• 13. Schoen K, Horvat N, Guerreiro NFC, de Castro I, de Giassi KS. Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity. BMC Infect Dis. 2019;19(1):964. Published 2019 Nov 12. doi:10.1186/s12879-019-4592-0
• 14. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020:1–13. Epub 2020/02/29. PubMed PMID: 32109013.
• 15. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention [published online ahead of print, 2020 Feb 24]. JAMA. 2020;10.1001/jama.2020.2648. doi:10.1001/jama.2020.2648
• 16. Onder G., Rezza G., Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 doi: 10.1001/jama.2020.4683. Epub 2020/03/24 PubMed PMID: 32203977.
• 17. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142. doi:10.1016/j.diabres.2020.108142
• 18. World Health Organization. Overview of the types/classes of candidate therapeutics 2020 [28/03/2020]. Available from: https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1.
• 19. Rekedal L.R., Massarotti E., Garg R., Bhatia R., Gleeson T., Lu B. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum. 2010;62(12):3569–3573. doi: 10.1002/art.27703. Epub 2010/08/20. PubMed PMID: 20722019; PubMed Central PMCID: PMCPMC2992611.
• 20. Gerstein H.C., Thorpe K.E., Taylor D.W., Haynes R.B. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas–a randomized trial. Diabetes Res Clin Pract. 2002;55(3):209–219. doi: 10.1016/s0168-8227(01)00325-4. Epub 2002/02/19. PubMed PMID: 11850097.
• 21. Palevsky PM, Radhakrishnan J, Townsend RR. Coronavirus disease 2019 (COVID-19): Issues related to kidney disease and hypertension. In: Up To Date [online]. Available at: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-issues-related-to-kidney-disease-and-hypertension? (Accessed July 1, 2020)
• 22. Kliger AS, Silberzweig J. Mitigating Risk of COVID-19 in Dialysis Facilities. Clin J Am Soc Nephrol 2020; 15:707.
• 23. Centers for Disease Control and Prevention. Interim Additional Guidance for Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed COVID-19 in Outpatient Hemodialysis Facilities. https://www.cdc.gov/coronavirus/2019-ncov/hcp/dialysis.html (Accessed on April 08, 2020).
• 24. American Society of Nephrology: Information for screening and management of COVID-19 in the outpatient dialysis facility, 2020. Available at: https://www.asn-online.org/g/blast/files/ DIALYSIS_COVID_2019_Update_03.13.2020_FINAL.pdf. Accessed March 19, 2020
• 25. Gosain R, Abdou Y, Singh A, Rana N, Puzanov I, Ernstoff MS. COVID-19 and Cancer: a Comprehensive Review. Curr Oncol Rep. 2020;22(5):53. Published 2020 May 8. doi:10.1007/s11912-020-00934-7
• 26. Uzzo RG, Kutikov A, Geynisman DM. Coronavirus disease 2019 (COVID-19): Cancer care during the pandemic. In: Up To Date [online]. Available at: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-cancer-care-during-the-pandemic? (Accessed July 1, 2020)
• 27. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic (Accessed on June 30, 2020)